

International Journal of PharmTech CODEN (USA): IJPRIF ISSN : 0974-4304

CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.2, No.1, pp 40-48, Jan-Mar 2010

Anxiolytic and Anticonvulsant Activity of Aqueous Extract of Stem Bark of *Erythrina variegata* in Rodents

G Pitchaiah¹, G L Viswanatha^{1*}, R Srinath¹, K Nandakumar², D.Dayabaran³, E.J.Florance⁴

¹Department of Pharmacology, PES College of Pharmacy, Bangalore, Karnataka. India. ²Department of Pharmacology, Manipal College of Pharmaceutical sciences, Manipal. India.

³Department of Pharmacology, Farooqia College of Pharmacy, Mysore, Karnataka. India. ⁴Department of Pharmacognosy, Farooqia college of Pharmacy, Mysore,Karnataka.India

*E mail : glv_000@yahoo.com , vishwaster@gmail.com Phone : 080 – 28485448, Mobile: +9198444 92334

Abstract: *Erythrina variegata* and some other species of genus *Erythrina* are known to act on central nervous system. In India, *Erythrina variegata* is the species generally used by the traditional practioners of south India for the treatment of mental illness. The anxiolytic effect of aqueous extract (100, 200 and 400 mg/kg) was evaluated by using elevated plus-maze(EPM) model, light-dark transition (LDT) model and open field test (OFT), while Pentylene tetrazole (PTZ), Maximal electroshock (MES) induced convulsions models were used to assess anticonvulsant activity in male swiss albino mice. Pretreatment with aqueous extract and estimation of GABA in rat brain tissues also performed to study the effect of aqueous extract (100, 200 mg/kg) on GABA levels of brain. Aqueous extract showed significant anxiolytic and anticonvulsant activity and also showed significant modulation of GABA levels in cerebellum and also in whole brain other than cerebellum.

Key words: Erythrina variegata; Anxiolytic; Anticonvulsant; GABA

1. Introduction

Anxiety affects one-eighth of total population of the world and become a very important area of research interest in psychopharmacology during this decade (Hwa et.al., 2005). Currently, the most widely prescribed medications for anxiety disorders are benzodiazepines. However, the clinical uses of benzodiazepines are limited by their side effects such as psychomotor impairment, potentiation of other central depressant drugs and dependence liability. Therefore, the development of new medications processing anxiolytic effect without the complications of benzodiazepines would be of great importance in the treatment of anxiety related disorders (Emanghoreishi et.al., 2005).

Epilepsy is the most common neurological disorder of the brain and is characterized by recurrent unprovoked seizures. The established antiepileptic drugs produce adverse effects such as ataxia, hepattoxicity and megaloblastic anaemia (Shindikar et.al., 2006). The use of herbal medicines by physicians in Europe and Asia, exploring their traditional remedies to find a suitable cure of these 'mind affecting diseases' and herbal medicines are often considered to be gentle and safe alternative to synthetic drugs (Rabbani et.al., 2004; Marjan et.al.,2007). At least 110 species of the genus Erythrina have been identified and many of them are native to the American continent. Erythrina plants produce alkaloids, flavonoids and terpenes and are also commonly used in folk medicine due to their tranquillizing effects (Ribeiro et.al., 2006).

Erythrina variegata belongs to the plant family Fabaceae. A wide spectrum of biological activities has been reported for different parts of the plant. Further folkore medicine suggests that Erythrina variegata barks acts on the central nervous system so as diminish or abolish its function. However there was lack of scientific data regarding its effect on the central nervous system.

Hence the present study was designed to evaluate the anxiolytic and anticonvulsant activity of aqueous extract of stem bark of Erythrina variegata and also to study the effect on GABA levels of the rat brain as this neurotransmitter plays an importment role in the pathogenesis of anxiety and epilepsy.

2. Materials and methods

2.1. Drugs and chemicals

Phenytoin (Sun Pharmaceuticals India.Ltd, Halol, India). Diazepam (Ranbaxy Laboratories Ltd, New Delhi, India), Pentylene tetrazole (Sigma-Aldrich, St.Louis, USA) were used for the study. All the solvents used for the extraction process are of Laboratory grade and they are purchased from local firms.

2.2. Plant material and preparation of extract

The stem bark of Erythrina variegata was supplied and authentified by Dr. Siddamallayya N, Regional Research Institute (RRI), Bangalore. The shade dried plant material was powdered. The coarse powder was subjected to successive extraction with petroleum ether, alcohol (70%) in soxhlet apparatus and the marc obtained after alcoholic extraction was macerated with chloroform water to obtain an aqueous extract.

2.3. Phytochemical investigation

The aqueous extract of Erythrina variegata (AQEEV) was subjected to preliminary qualitative investigations (Khandelwal., 1996.).

2.4. Experimental animals

Swiss albino mice of either sex (18-25g) was procured from Bioneeds, Bangalore and all were acclimatized for 7 days in the animal house of P.E.S. College of Pharmacy, Bangalore. Male Wistar albino rats (120-150g) were obtained from National Toxicology Centre, Pune and were acclimatized at the animal house of Poona College of Pharmacy, Pune. All the animals were maintained under standard conditions, i.e. room temperature $26 \pm 1^{\circ}$ C, Relative humidity 45-55% and 12:12 h light- dark cycle. The experimental protocols were approved by the Institutional Animal Ethics Committee (IAEC) of PES College of Pharmacy, Bangalore and all the experiments were conducted according to the guidelines of Committee for the Purpose of Control and Supervision on Experiments on Animals (CPCSEA).

2.5. Acute toxicity studies

Acute oral toxicity of aqueous extract of stem bark of Erythrina variegate was determined by using female, nulliparous and non pregnant mice weighing 18-22 g. The animals were fasted for 3 hrs prior to the experiment. Up and down procedure OECD guideline no. 425 was adopted for toxicity studies. Animals were administered with single dose of extract and observed for their mortality during 48 hours study period (short term) toxicity. LD_{50} was calculated as per OECD guidelines 425 using AOT 425 software (OECD guidelines no.425, 2001).

2.6. Pharmacological experiments

2.6.1. Anxiolytic activity

(i) Elevated Plus Maze model

The Elevated plus-maze test is described elsewhere (Hogg, 1996: Rodger et al., 1997). The apparatus comprises of two open arms (35 cm \times 5 cm) and two closed arms (30 cm \times 5 cm \times 15cm) that extend from a common central platform (5 cm \times 5 cm). The floor and walls of the closed arms is wooden and painted black.

The entire maze is elevated to height of 50 cm above the floor level (Lister, 1987). Mice of 18-22 were housed in pair for 10 days prior to testing in the apparatus. During this time the mice are handled by the investigator on alternate days to reduce stress. A group consists of 6 mice for each dose. One hour after the Vehicle/Standard/Extract treatment, each mouse was placed in the center of the maze facing one of the open arms. During a five minutes test period the following measures were taken: the number of entries into and the time spent in the open and the closed arms, time spent in central zone and rearing. The procedure was conducted preferably in a sound attenuated room.

(ii) Open Field

Spontaneous motor activity was evaluated in open field test (Bhattacharya et.al., 1997). The open field apparatus is made up of plywood and consisted of square 56 cm x 56 cm. The entire apparatus was painted black and 6mm thick white lines divided the floor into 16 square of identical dimension.

Open field was lighted by 40 W bulb focusing on to the field from the height of about 100cm. The entire room, except the open field was kept dark during the experiment. One hour after Vehicle/Standard/Extract treatment each animal was placed at one corner of the apparatus and the following behavioral aspects were noted in the next 5min.

a) Latency: Time taken by animal to leave square in which it was placed.

- b) Time taken to enter central compartment.
- c) Total locomotion and central locomotion.

d) Ambulation: Number of squares passed by animal.

e) Rearing: Number of times animal stood on its hind leg.

(iii) Light-Dark model

Natural aversion of animal for brightly lit places was evaluated in light-dark transition model (Crawley and Goodwin, 1980). Light dark box is a rectangular box of 46 x 27x 30cm (1 x b x h), which is divided into 2 compartments. $1/3^{rd}$ is for the dark compartment and $2/3^{rd}$ is served as light compartment. One hour after the Vehicle/Standard/Extract treatment, the mouse were placed individually in the light compartment and observe for a period of 5 min. Parameters like total locomotion in light zone, number of rearing, time spent in light and dark zones and number of crossings/entries in the each zone were observed during this period.

2.6.2. Anticonvulsant activity

(i) <u>PTZ (Pentylene tetrazole) induced convulsions</u>

Effect of AQEEV was tested against chemically induced convulsions (Khosla and Pandhi, 2001). Male albino mice weighing between 20-25g were divided into five groups each comprising of six animals. One hour after Vehicle/Standard/Extract treatment, PTZ (Pentylenetetrazole 80 mg/kg s.c.) was administered to all groups of mice. Each animal was placed in to individual plastic cage and were observed initially for 30min and later up to 24 hrs. The following parameters were recorded during test session of initial 30min and at the end of 24 hrs; Latency (onset of clonus), Onset of tonic convulsions and status of animal after 24 hrs.

(ii) Maximal Electro Shock (MES) induced **convulsions**

Effect of AQEEV was tested against electrically induced convulsions (Swinyard et.al., 1952). Briefly, a 60mA current was delivered transauricularly for 0.2 sec in mice via small alligator clips attached to each pine by electroconvulsometer, this current intensity will elicit complete tonic extension of the hind limbs in control mice.

For recording various parameters, 30 mins after the Vehicle/Standard/Extract treatment the mice were placed in a rectangular plastic cage with an open top, permitting full view of animal's motor responses to seizure in the pilot study of various phases of convulsions, viz. tonic flexion, extension, stupor and mortality due to convulsions are selected as the parameters (Vogel and Vogel., 2000.).

2.6.3. Estimation of GABA levels in rat brain

Effect of AQEEV on GABA levels in brain was also package. studied (Suher et.al., 2000). Briefly, after three days treatment with aqueous extract/standard, animals were 3. Results killed by euthanasia and the body was exposed to a 3.1 Phytochemical investigation microwave irradiation for 4 sec.

The brain was rapidly removed and the cerebellum, the tissue other than cerebellum were dissected on an icecold petri dish. The tissues were placed after weighing in pre-cooled 100 ml plastic tubes. Ice-cooled 0.1M perchloric acid (10 ml) which contained valine (internal standard) at a concentration of 15 µg/ml was added to the tissue. The tissues were homogenized for one minute during which the tube was embedded in an ice bath and then centrifuged at 5,000 rpm for 10 min at 4°C. The supernatants were stored at -20°C until assayed. Dansylation reaction was induced. Dansylation was carried out by adding 100 µl of each supernatant of the samples or the standards to a microtube containing 100 µl of 0.1M potassium carbonate solution. These solutions were mixed using vortex and then centrifuged using microcentrifuge at 10,000 rpm for 10 min. 100 µl of each supernatant was transferred into a pyrex tube containing 100 µl of 0.1M sodium hydrogen carbonate solution, to which 400 µl of working dansyl chloride solution (1.25 mg/ml anhydrous acetone) was added. The tubes were shaken for 30 sec using vortex and then incubated at 90°C in benchtop oven for 30 min.

The tubes were not capped during the incubation to allow most of the solvent to be evaporated. This did not appear to adversely affect the progress of the dansylation reaction and served to concentrate the samples.

After getting the tubes out of the oven, they were left to cool down to room temperature and the dansylated derivatives were transferred to 1.5 ml microtubes and stored at -20°C until assayed. C8 reversed-phase HPLC columns (5 µm, 250 x 3.2 mm) were used to resolve and quantify the samples. The HPLC mobile phase consisted of deionized helium degassed wateracetonitrile (HPLC grade) mixture (65:35 v/v) containing 0.15% v/v phosphoric acid. The flow rate was kept at 0.5 ml/min.

The detector excitation was at 333 nm and emission at 532 nm. 25 µl of the dansyl derivative of the GABA samples were transferred to HPLC micro-sample vials and injected into the column. Retention time of GABA and internal standard were determined.

The peak ratios of the samples were calculated with reference to the internal standard. GABA levels were expressed as ng/g of tissue.

2.6.4 Statistical Analysis:

Values were expressed as mean ± SEM from 6 animals. Statistical difference in mean was analyzed using one way ANOVA (analysis of variance) followed by followed by Tukey-kramer test and p<0.05 was considered significant. All the analysis was made using the INSTAT statistical software

This study revealed that aqueous extract of E.variegata contains alkaloids, flavonoids, terpenes and glycosides as major constituents.

3.2 Acute toxicity

No mortality was observed upto 2000 mg/kg dose. Hence aqueous extract of E.variegata was found to be safe upto 2000 mg/kg.

3.3 Pharmacological behavioral screening

3.3.1 Anxiolytic activity

(i) <u>Elevated plus-maze (EPM) behavior</u>

The aqueous extract at medium (200 mg/kg) and high (400 mg/kg) dose levels showed significant increase in the number of entries into open arm and time spent in open arm compared vehicle control group and these results were comparable with the reference drug diazepam.

On the other hand the effect of low dose (100 mg/kg) on time spent in open arm was significant but not on number of entries into open arm and these results were shown in **Table 1.**

(ii) **Open-Field Test**

Significant increase in the total locomotion, time spent in central compartment and ambulation was observed with 200 mg/kg and 400 mg/kg doses of extract but the effect of low dose (100 mg/kg) of AQEEV on these parameters was insignificant. The other parameters including rearing were not significantly modified by all three doses used. These effects were shown in **Table 2.**

(iii) Light-Dark Transition model

Aqueous extract (100, 200 and 400 mg/kg) had increased the latency to the first crossing to the dark zone. AQEEV at medium (200 mg/kg) and high (400 mg/kg) doses showed significant increase in the time spent in light zone, total locomotion time in light zone along with number of crossings between light and dark zones compared to control group which indicates the reduced fear of animal. These effects were shown in **Table 3.**

3.3.2 Anticonvulsant activity

(i) PTZ (Pentylene tetrazole) induced convulsions

Pretreatment with aqueous extract (100, 200, 400 mg/kg) showed significant alteration in the onset of tonic - clonic seizures compared to control group animals and also showed protection against PTZ induced mortality in a dose dependent manner but the extract was failed to abolish the seizures. These effects were shown in **Table 4**.

(ii)<u>MES (Maximal Electro Shock) induced</u> <u>convulsions</u>

Aqueous extract (200 and 400 mg/kg) of E. variegata significantly increased the onset of clonus and decreased the duration of extensor phase along with abolition of flexion phase of grandmal seizures. Extract also showed protection against mortality in a dose dependent manner.

Low dose (100 mg/kg) of AQEEV had not shown significant effect on these parameters. These effects were shown in **Table 5**.

3.3.3 Estimation of GABA levels in rat brain

Pretreatment with AQEEV (100 and 200 mg/kg) for three days had increased the GABA levels in cerebellum and also in whole brain other than cerebellum. Similar effect was observed with diazepam (2 mg/kg). However, the effect of AQEEV was less than diazepam (2 mg/kg). These effects were shown in **Table 6**.

4. Discussion and Conclusion

In our study, the anxiolytic effect of aqueous extract of stem bark of Erythrina variegata was studied in elevated plus-maze, open field test and light-dark transition models. These are the classical animal models to evaluate axiolytic effect of a compound. Diazepam, a standard anxiolytic used clinically and is also employed in behavioral pharmacology as a reference compound for inducing anxiolytic-like effects, even when the compound being screened does not act via benzodiazepine receptors (Soderphalam et.al., 1989). Measuring anxiety like behavior in mice has been mostly undertaken using a few classical animal models of anxiety such as the Elevated Plus Maze (EPM) Light Dark Model (LDM) and Open Field Test (OFT). All these procedures are based upon the exposure of subject to unfamiliar aversive place (Belzung and Griebel., 2001.).

Pretreatment with aqueous extract stem bark of Erythrina variegata showed significant anxiolytic activity in EPM by increasing the number of entries and time spent in open arm, and in LDM by increasing the time spent in light zone and number of crossings between light and dark zones, and in OFT model by increasing the time spent in central compartment and ambulation.

Epilepsy is one of the most common serious neurological conditions. Seizure refers to a transient alteration of behaviour due to disordered, synchronous and rhythmic firing of populations of brain neurons (Noel et al.,2008.)

For measuring the anticonvulsant activity in mice has been mostly undertaken using a few classical animal models such as the PTZ induced convulsions are assumed to identify anticonvulsant drugs effective against generalized tonic-clonic partial seizures and MES induced convulsions are assumed to identify generalized clonic seizures respectively (Madhavan et al., 2008; Cristiana et.al., 2006; Atif et al.,2005.). Studies have proved that the agents which increase the brain GABA content and administration of centrally active GABA mimetic agents have been used as an effective therapeutic approach for treatment of epilepsy Hence to see the effect of the extract on GABA levels different parts of the brain, the animals are treated with the extracts and GABA levels are estimated by HPLC method (Suher et.al., 2000.).

Aqueous extract of stem bark of Erythrina variegata showed significant anticonvulsant activity by increasing the onset of clonus and tonic phases in PTZ induced convulsion model, and in MES induced convulsion model by increasing the duration of tonic extensor phase.

GABA appears to play an important role in the pathogenesis of several neuropsychiatric disorders. Many of the traditional agents used to treat psychiatric disorders are known to act, at least in part, by enhancing GABA activity, while some of the newer agents may exert their therapeutic effects exclusively via GABAergic actions. In our present study, three days treatment with AQEEV and further GABA estimation in brain showed significant enhancement of GABA levels in cerebellum and whole brain other than cerebellum compared to control group.

These findings suggests that the aqueous extract of stem bark of Erythrina variegata possess significant anxiolytic and anticonulsant activity and modulation of GABA levels in brain might be the reason for anxiolytic and anticonvulsant activities.

5.Acknowledgment

The authors are thankful to Prof.Dr.S.Mohan, Principal and management members of P.E.S.College of Pharmacy, Bangalore for providing all necessary facilities to carry out the research work. Special thanks to Dr.Siddhamallayya, Regional Research Institute, Bangalore for his support and help to get authentified plant material.

	Elevated plus maze model						
TREATM ENTS	NUMBER OF ENTRIES (COUNTS/5MIN)		TIME SPENT IN (SEC/5MIN)		TIME SPENT IN NEUTRAL ZONE (COUNTS/5MIN)	REARING (Counts/ 5min)	
	OPEN ARM	CLOSED ARM	OPEN ARM	CLOSED ARM			
Control (3%tween 80)	3.66±0.55	13.16±1.22	29.16±7.94	218.16±14.28	52.66±7.67	4.83±0.47	
Diazepam (2 mg/kg)	12.16±1.04 [*]	15.16±1.04	137.16±9.33***	142.83±7.71***	20.0±3.49**	7.33±0.55	
AQEEV (100 g/kg)	5.66±1.02	13.16±1.01	76.5±7.89 [*]	183.83±12.39	39.33±7.11	5.16±0.94	
AQEEV (200mg/kg)	10.33±1.14 [*]	4.16±1.16	129.5±11.00***	148.66±8.60***	21.83±5.16*	5.83±1.01	
AQEEV (400mg/kg)	10.66±1.35 [*]	13.5±1.05	133.66±9.97***	145.16±8.07***	21.16±5.12**	5.83±0.79	

Values are expressed as mean \pm SEM from 6 mice. $P \le 0.05^*$, $\le 0.01^{**}$ and $\le 0.001^{***}$ as compared to control group

Treatments	Time spent in square where it is placed (Sec/5min)	Time taken to enter central compartment (Sec/5min)	Total locomotion (sec/5min)	Central locomotion (sec/5 min)	Ambulation (Counts/5min)	Rearing (Counts/min)
Control (3%tween 80)	9.33±1.78	44.50±8.08	164.16±19.52	11.16±2.52	61.83±6.95	7.33±1.60
Diazepam (2 mg/kg)	3.83±0.79*	24.16±4.23	271.66±8.77***	44.16±6.43**	173.33±16.20***	14.66±1.54*
AQEEV (100 mg/kg)	6.66±1.58	32.50±5.01	206.33±22.76	26.16±5.78	111.66±11.39	8.83±0.90
AQEEV (200 mg/kg)	4.50±0.99	26.16±4.61	262.50±12.66**	40.16±4.59*	168.50±14.32***	11.50±0.80
AQEEV (400 mg/kg)	4.16±0.70	23.33±6.19	263.83±11.28**	39.66±7.88*	161.16±21.85**	11.16±1.49

Table 2: Effect of AQEEV on Open Field Test in mice

Values are expressed as mean \pm SEM from 6 mice. $P < 0.05^*$, $< 0.01^{**}$ and $< 0.001^{***}$ as compared to control group

Treatments	Latency (sec)	Time spent in dark zone (sec/5 min)	Time spent in light zone (sec/5 min)	No. of crossings (Counts/5min)	Total locomotion time in light zone (sec/5min)	Rearing (Counts/5min)
Control (3%tween 80)	10.16±1.86	206.83±9.30	93.16±9.30	4.83±0.70	60.33±6.31	7.66±1.40
Diazepam (2 mg/kg)	19.16±3.13	107.83±8.91***	192.16±8.91***	11.33±0.98*	174.33±10.51***	9.66±0.95
AQEEV (100 mg/kg)	13.33±1.94	170.16±16.22	129.83±16.22	7.16±1.37	106.33±16.59	8.83±1.30
AQEEV (200 mg/kg)	18.33±2.98	141.16±18.60*	158.83±18.60*	9.16±1.62	141.83±19.22**	8.83±0.87
AQEEV (400 mg/kg)	21.66±3.20	103.66±14.07***	196.33±14.07***	12.83±1.62**	177.33±15.35***	9.16±1.30

Table 3: Effect of AQEEV on Light-dark transition model

Values are expressed as mean \pm SEM from 6 mice. $P \le 0.05^*$, $\le 0.01^{**}$ and $\le 0.001^{***}$ as compared to control group

Treatments	Latency (onset of Clonus) (Sec/30min)	Onset of Tonic (Sec/30min)	% Protection against seizures	% Protection against mortality
Control (3%tween 80)	51.83±5.48	369.16±23.64	0	0
Diazepam (5 mg/kg)	No clonus	No tonus	100	100
AQEEV (100 mg/kg)	110.66±11.23*	440.16±40.97	0	16.66
AQEEV (200 mg/kg)	155.83±17.53***	503.16±27.30*	0	50
AQEEV (400 mg/kg)	211.16±16.50***	570.16±39.64***	0	66.66

Table 4: Effect of AC	DEEV on PTZ-induced	convulsions model
		convulsions mouch

Values are expressed as mean±SEM from 6 mice. *P*<0.05* and <0.001*** as compared to control group

Treatments	Duration of tonic flexion (Sec/30min)	Duration of tonic extensor (Sec/30min)	Latency (onset of clonus) (Sec/30min)	% Protection against mortality (24h)
Control (3%tween 80)	Not observed	15.33±0.55	2.16±0.47	0
(Phenytoin (25 mg/kg)	6.83±0.79***	Not observed***	13.16±1.35***	100
AQEEV (100 mg/kg)	Not observed	13.16±1.19	4.16±0.79	33.33
AQEEV (200 mg/kg)	Not observed	9.66±1.02**	8.16±1.49**	50
AQEEV (400 mg/kg)	Not observed	7.66±1.08***	9.16±1.01***	83.33

Table 5: Effect of ALEEV and AQEEV on MES induced convulsions

Values are expressed as mean±SEM from 6 mice. P<0.01** and <0.001*** as compared to control group

Treatments	In cerebellem (ng/g of tissue)	In whole brain other than cerebellem (ng/g of tissue)
Control (3%tween 80)	423.83±16.61	2228.83±48.01
(Diazepam 2 mg/kg)	1929.13±51.86***	5946.74±56.46***
AQEEV (100 mg/kg)	772.90±25.05***	3248.74±60.03***
AQEEV (200 mg/kg)	1299.74±73.61***	4835.36±96.72***

 Table 6: Effect of AQEEV on GABA levels in brain.

Values are expressed as mean \pm SEM from 6 mice. $P < 0.001^{***}$ as compared to control group

References

- 1. Atif A, Farhan JA, Krishna KP, Divya V. Amiloride protects against pentylenetetrazoleinduced kindling in mice. Br. J. Pharmacol 2005; 145; 880–884.
- 2. Belzung C, Griebel G. Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav. Brain Res. 2001; 125(1-2):141-149.
- Bhattacharya, S.K., Satyan. K.S., 1997. Experimental methods for evaluation of psychotropic agents in rodents. Indian journal of experimental biology 35, 565-75.
- 4. Crawley, J., Goodwin, F.K., 1980. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacology, biochemistry, and behavior 13, 167.
- Cristiana, M., Murbach, F., Marcia, O.M., Marques., Mirtes, C., 2006. Effects of seasonal variation on the central nervous system activity of *Ocimum grastissimum* L. essential oil. Journal of Ethnopharmacology 105, 161-166.
- 6. Emamghoreishi M, Khasaki M, Aazam MF. *Coriander sativum*: evaluation of its anxiolytic effect in the elevated plus-maze. Journal of Ethnopharmacology 2005; 96:365-70.
- Hwa, Y.C., Jeong, H.P., Jin, T.H., Hwan, S.Y., Sukjil, S., Bang, Y.H., et.al. 2005. Anxiolytic-Like Effects of Gensinosides on the Elevated Plus-Maze Model. Biological & pharmaceutical bulletin 28(9), 1621-1625.

- 8. Hogg, S.A., 1996. Review of the validity and Variability of the elevated plus-maze as an animal model of anxiety. Pharmacology, biochemistry, and behavior 54, 21-30.
- 9. Khandelwal, K.R., 2000. "Practical Pharmacognosy-techniques and experiments". Nirali Prakashan, Pune, India, p.149-155.
- 10. Khosla, P., Pandhi, P., 2001. Anticonvulsant effect of nimodipine alone and in combination with diazepam on PTZ induced convulsions. Indian Journal of Pharmacology 33, 208-11.
- 11. Lister, R.G., 1987. The use of a plus maze to measure anxiety in the mouse. Psychopharmacology 92, 180-5.
- 12. Madhavan V, Hemalatha HT, Anita M, Yoganarasimhan S.N. Antiepileptic activity of alcohol and aqueous extracts of roots and rhizomes of *smilax zeylanica* linn. *Pharmacologyonline* 2008: 3: 263-272.
- Marjan, N.A., Schwann, S.R., Farzaneh, Z., 2007. Anticonvulsant effects of aerial parts of *Passiflora incarnata* extract in mice: involvement of benzodiazepine and opioid receptors. BMC complementary and alternative medicine 7, 216.
- Nadkarni, K.M., 1976. Nadkarni AK (Eds). Indian Meteria Medica.3rd ed. Bombay: Popular Prakashan
- 15. Noel NW, Joseph AA, Helen OK, Steven SG, Asa A. Anti-seizure activity of the aqueous leaf extract of *Solanum nigrum* linn (solanaceae) in experimental animals. *African Health Sciences* 2008; 8(2): 74-79.

- OECD 2001-gudeline on acute oral toxicity (AOT) Environmental health and safety monograph series on testing and adjustment No.425.
- Rabbani, M., Sajjadi, S.E., Zarei, H.R., 2003. Anxiolytic effect of *Stachys lavandulifolia* Vahl on the elevated plus-maze model of anxiety in mice. Journal of Ethnopharmacology 89, 271-276.
- 18. Ribeiro, M.D., Onusic, G.M., Poltronieri1, S.C., Viana, M.B., 2006. Effect of *Erythrina velutina* and *Erythrina mulungu* in rats submitted to animal models of anxiety and Depression. Brazilian journal of medical and biological research 39(2), 263-70.
- Rodgers R.J., Cao, B.J., Dalvi, A., Hobnes, A., 1997. Animal models of anxiety: An ethological perspective. Brazilian journal of medical and biological research 30, 280-304.
- 20. Role of GABA in the Pathogenesis and Treatment of anxiety and other neuropsychiatry disorders. <u>www.vcu-cme.org</u>. (Cited on 15th January 2008).

- Shindikar, A.V., Khan, F., Viswanathan, C.L., 2006. Design, synthesis and in vivo anticonvulsant screening in mice of Novel phenylacetamides. European journal of medicinal chemistry 41,786-792.
- 22. Soderphalam, R., Hjorth, S., Engel, J.A., 1989. Pharmacology, biochemistry, and behavior 32, 259-265.
- 23. Suher, M.A., Abdullah, S.E., Saleem, S.A., Samir F.S., Amina S.A., 2000. Effects of acute and chronic Triazolam treatments on brain GABA levels in albino rats. Acta neurobiologiae experimentalis 60, 447-455.
- Swinyard, E.A., Brown, W.C., Goodman, L.S., 1952.Comparative assays of antiepileptic drugs in mice and rats. Journal of Pharmacological Experiments and Therapeutics 106, 319-30.
- Vogel H.G, Vogel WH. (Eds) Drug discovery and Evaluation Pharmacological assays (Springer). 2000; 2: (E) 230-244.
